Home » Revestive Gets European Marketing Authorization for Short Bowel Syndrome
Revestive Gets European Marketing Authorization for Short Bowel Syndrome
Takeda Pharmaceutical and NPS Pharmaceuticals said the European Commission has granted European market authorization for the medicinal product teduglutide or Revestive as a once-daily treatment for adult patients with short bowel syndrome.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May